ReviewNature reviews. Gastroenterology & hepatology2020
Antidepressants in inflammatory bowel disease.
Review in Nature reviews. Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Exploring Electrical Neuromodulation as an Alternative Therapeutic Approach in Inflammatory Bowel Diseases.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Interventions for the management of abdominal pain in ulcerative colitis.The Cochrane database of systematic reviews · 2021Pooled it
- Duloxetine as a gut-brain axis modulator in irritable bowel syndrome: neuroimmune, microbiota, and pharmacogenomic perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Development and validation of a model incorporating choroid plexus morphology from brain MRI to predict anti-TNF-α therapy outcomes in Crohn's disease.BMC gastroenterology · 2026Article
- Stress-Induced Activation of Prolactin-NR4A1-Midkine Axis Exacerbates Skin Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Magnoflorine alleviates colitis-induced anxiety-like behaviors by regulating gut microbiota and microglia-mediated neuroinflammation.Microbiome · 2025Article
- From gut inflammation to psychiatric comorbidity: mechanisms and therapies for anxiety and depression in inflammatory bowel disease.Journal of neuroinflammation · 2025Review
- Consensus Statement on Managing Anxiety and Depression in Individuals with Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Antidepressants for inflammatory bowel disease? Multimodal effects of amitriptyline in murine colitis.The Journal of pharmacology and experimental therapeutics · 2025Article
- Quality of Life in Patients with Inflammatory Bowel Diseases Is Associated with Affective Temperament Traits: A Cross-Sectional Survey of a Polish Clinical Sample.Journal of clinical medicine · 2025Article
- Using metabolomics to investigate the relationship between the metabolomic profile of the intestinal microbiota derivatives and mental disorders in inflammatory bowel diseases: a narrative review.Research in pharmaceutical sciences · 2025Review
- Serotonin attenuates tumor necrosis factor-induced intestinal inflammation by interacting with human mucosal tissue.Experimental & molecular medicine · 2025Article
- Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study.Alimentary pharmacology & therapeutics · 2025Article
- Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians.Digestive diseases and sciences · 2024Review
- Antidepressant fluoxetine alleviates colitis by reshaping intestinal microenvironment.Cell communication and signaling : CCS · 2024Article
- Clinical outcomes associated with antidepressant use in inflammatory bowel disease patients and a matched control cohort.Scientific reports · 2024Article
- Exposure-based cognitive behavioral therapy with complementary awareness and emotional expression training for alleviating irritable bowel syndrome (IBS).Gastroenterology and hepatology from bed to bench · 2024Article
- The anti-inflammatory effects of antidepressants on colitis.Gastroenterology and hepatology from bed to bench · 2024Article
- Chronic abdominal pain in inflammatory bowel disease: a practical guide.Frontline gastroenterology · 2024Review
- Kynurenine pathway and its role in neurologic, psychiatric, and inflammatory bowel diseases.Molecular biology reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut-brain dysregulation has been recognized by the scientific community as being crucial to the understanding of chronic gastrointestinal conditions, and this has translated into the practice of a newly established discipline, psychogastroenterology. Along with psychotherapy, antidepressants (a subtype of central neuromodulators) have been proposed as treatments for gut-brain disorders that might benefit both psychological and gastrointestinal health. Antidepressants have been found to be effective for the treatment of comorbid anxiety and depression, pain and impaired sleep. Although the efficacy of antidepressants is well established in disorders of gut-brain interaction (DGBI), evidence is only now emerging in IBD. This Perspective discusses the use of antidepressants in DGBI and IBD, focusing on how what we have learnt about the role of antidepressants in DGBI could be applied to help optimize the management of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.